Using Trilaciclib with Chemotherapy for Osteosarcoma Treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of Trilaciclib in protecting bone marrow during neoadjuvant chemotherapy for patients with stage II/III classic osteosarcoma. The study combines Trilaciclib with pirarubicin and lobaplatin to assess its ability to reduce chemotherapy-induced myelosuppression, which can lead to severe complications and affect treatment compliance. By blocking CDK4/6 activity, Trilaciclib aims to preserve hematopoietic stem cells and enhance the overall efficacy of chemotherapy. The trial will involve patients who are newly diagnosed and have measurable disease as confirmed by imaging.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Written informed consent signed;
2. Classic osteosarcoma confirmed by histopathology (high grade);
3. Newly diagnosed stage Ⅱ-Ⅲ based on Enneking staging criteria;
4. Planned to receive neoadjuvant chemotherapy;
5. Measurable disease on CT by RECIST 1.1.
6. No antitumor system therapy received;
7. ECOG 0-1
8. Adequate organ function.
9. Females of childbearing potential as well as males and their partners must agree to use an effective form of contraception during the study and for 6 months following the last dose of study medication.

Exclusion Criteria:

1. History of malignancies of other type;
2. Allergic to study agent;
3. History of psychotropic substance abuse, alcohol or drug use;
4. The researchers considered inappropriate to join the study of any cause.

Where it's running

• Peking University People's Hospital
  Beijing, Beijing Municipality, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Fight Osteosarcoma with a European, evolving research platform from diagnosis to relapse

  A European platform trial in pediatric and young adult high-grade osteosarcoma will test Cabometyx as one treatment option while collecting tumor and blood samples to guide future strategies.

  Recruiting Phase 3 Gustave Roussy, Cancer Campus, Grand Paris · Aarhus and 76 other locations · NCT07871864

• Immunotherapy plus standard treatment for high-risk osteosarcoma in kids and young adults

  This study tests mifamurtide added to standard chemotherapy versus standard treatment with sorafenib to see if the combination helps patients with high-risk osteosarcoma.

  Recruiting Phase 2 Institute of Mother and Child, Warsaw, Poland · Warsaw, Mazovian · NCT07787429

• 68Ga-B7-H3 Nanobody PET Imaging in Osteosarcoma

  This study tests a new gallium-68 labeled B7-H3 nanobody to see if it can image osteosarcoma tumors more clearly.

  Recruiting Early Phase 1 Peking University First Hospital · Beijing, Beijing Municipality · NCT07774533

• Domatinostat with Sirolimus for relapsed or refractory sarcoma and osteosarcoma

  This study tests whether the cancer drugs domatinostat and sirolimus together can help adolescents and adults whose sarcoma or osteosarcoma has come back or stopped responding to standard therapy.

  Recruiting at 2 sites Phase 1/2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida and 3 other locations · NCT07725380

• Neoantigen Vaccine SarVac With Tumor-Specific Lymphocytes Plus PD-1 Blocker for Advanced Sarcoma

  This trial tests a personalized cancer vaccine called SarVac, given with a PD-1 blocker, and possibly tumor-specific lymphocytes, to see if it is safe and can help people with advanced soft tissue or bone sarcoma.

  Recruiting Phase 1 Sun Yat-sen University · Guangzhou, Guangdong · NCT07648069

• Methionine-Reduced Diet in Solid Tumors (early-phase)

  A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.

  Recruiting Early Phase 1 University of California, Irvine · Orange, California · NCT07628634

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.